Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tylenol Extra Strength Liver Damage Litigation Fails On ‘Ambiguity’ Of Use

This article was originally published in The Tan Sheet

Executive Summary

McNeil says the verdict a New Jersey state court jury rendered “reflects the facts of this case” while the plaintiff’s lawyers contend the “heart” of the case – safety of using the drug according to the label directions – was not addressed.

You may also be interested in...



Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial

J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.

Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial

J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.

McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel